Testing effectiveness (Phase 2)Looking for participantsNCT05749588What this trial is testingFUSCC Refractory TNBC Platform Study (FUTURE2.0)Who this might be right forTriple-negative Breast Cancer Fudan University 120
Testing effectiveness (Phase 2)WithdrawnNCT05539365What this trial is testingDendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerWho this might be right forAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+1 more Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT05035745What this trial is testingSelinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)Who this might be right forAdvanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers National University Hospital, Singapore 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07419880What this trial is testingRe-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast CancerWho this might be right forTriple -Negative Breast Cancer Fudan University 46
Testing effectiveness (Phase 2)Ended earlyNCT03435640What this trial is testingREVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesWho this might be right forMelanomaMerkel Cell CarcinomaTriple Negative Breast Cancer+4 more Nektar Therapeutics 64
Early research (Phase 1)Looking for participantsNCT06799065What this trial is testingFirst-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerWho this might be right forAdvanced Solid TumorsBreast Cancer RecurrentOvarian Cancer+2 more Accent Therapeutics 90
Early research (Phase 1)Ended earlyNCT02706392What this trial is testingGenetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesWho this might be right forHematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Lung Non-Small Cell Carcinoma+10 more Fred Hutchinson Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT01631552What this trial is testingStudy of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerWho this might be right forGastric AdenocarcinomaEsophageal CancerHepatocellular Carcinoma+13 more Gilead Sciences 515
Testing effectiveness (Phase 2)UnknownNCT03805399What this trial is testingFUSCC Refractory TNBC Umbrella (FUTURE)Who this might be right forTriple-negative Breast Cancer Fudan University 140
Testing effectiveness (Phase 2)Study completedNCT02403271What this trial is testingA Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsWho this might be right forNon-Small Cell Lung CancerBreast CancerPancreatic Cancer Pharmacyclics LLC. 124
Early research (Phase 1)Looking for participantsNCT06586957What this trial is testingA Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsWho this might be right forSolid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more NiKang Therapeutics, Inc. 150
Early research (Phase 1)Active Not RecruitingNCT04485013What this trial is testingTTX-080 HLA-G Antagonist in Subjects With Advanced CancersWho this might be right forCancer Tizona Therapeutics, Inc 240
Early research (Phase 1)Ended earlyNCT06264921What this trial is testingA Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsWho this might be right forSolid TumorSolid Tumor, AdultAdvanced Solid Tumor+26 more NiKang Therapeutics, Inc. 23
Early research (Phase 1)UnknownNCT02580747What this trial is testingTreatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-mesoWho this might be right forMalignant MesotheliomaPancreatic CancerOvarian Tumor+3 more Chinese PLA General Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108What this trial is testingLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasWho this might be right forBone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT03997968What this trial is testingCYT-0851 in B-Cell Malignancies and Advanced Solid TumorsWho this might be right forMalignancyNon-hodgkin LymphomaMultiple Myeloma+12 more Cyteir Therapeutics, Inc. 169
Early research (Phase 1)Study completedNCT01837095What this trial is testingDose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Polyphor Ltd. 54
Early research (Phase 1)Looking for participantsNCT07029399What this trial is testingA Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsWho this might be right forHR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more NiKang Therapeutics, Inc. 361
Early research (Phase 1)Study completedNCT02898207What this trial is testingOlaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerWho this might be right forMetastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more National Cancer Institute (NCI) 28
Early research (Phase 1)Active Not RecruitingNCT04514484What this trial is testingTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVWho this might be right forAdvanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more National Cancer Institute (NCI) 8